Hoth Therapeutics

General Information


We are a development-stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. We were incorporated in Nevada in May 2017 and have a limited operating history. Our primary asset is a sublicense agreement with Chelexa pursuant to which Chelexa has granted us an exclusive sublicense to use its BioLexa Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The license enables us to develop the platform for any indications in humans. Our initial focus will be on the treatment of eczema through the application of a topical cream.

Employees: 2
Founded: 2017
Contact Information
Address 1 Rockefeller Plaza, Suite 1039, New York, NY 10020, US
Phone Number (646) 756-2997
Web Address
View Prospectus: Hoth Therapeutics
Financial Information
Market Cap $52.77mil
Revenues $0 mil (last 12 months)
Net Income $-1.9 mil (last 12 months)
IPO Profile
Symbol HOTH
Exchange NASDAQ
Shares (millions): 1.3
Price range $5.60 - $5.60
Est. $ Volume $7.0 mil
Manager / Joint Managers Laidlaw & Company (UK) Ltd.
CO-Managers -
Expected To Trade: 2/15/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change